Norwegian Institute of Public Health
John-Arne Røttingen, the director of the Division of Infectious Disease Control at the Norwegian Institute of Public Health and adjunct professor of Global Health and Population at Harvard University, is one of the co-authors of the successful rVSV-ZEBOV Ebola vaccine trial. He worked alongside the WHO, Wellcome Trust, the government of Canada, MSF, the London School of Hygiene and Tropical Medicine and manufacturers Merck and NewLink.